New drug slows advanced kidney cancer

	Tweet

In patients with a type of kidney cancer—Renal cell carcinoma (RCC)—that has spread to other parts of the body may be helped by a dual-action drug called sorafenib, according to preliminary results of a clinical trial reported this week.

In fact, outcomes were so positive that the US Food and Drug Administration is allowing sorafenib to be made available to patients with advanced RCC before its formally approved, according to a press release from Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals Inc.

Sorafenib inhibits tumor cell growth by targeting both a key enzyme and a growth factor receptor involved in the process, Dr. Bernard Escudier, from Gustave-Roussy Institute in Paris, and colleagues note in their meeting report at the American Society for Clinical Oncology conference.

Investigators in the multinational study randomly assigned 769 patients with previously treated, advanced Renal cell carcinoma to either treatment with sorafenib or to supportive care.

Average survival time free of disease progression was 24 weeks in the sorafenib group and 12 weeks in the supportive care group. By 12 weeks, 79 percent of the patients on sorafenib remained stable compared with 50 percent of the others.

These results are “clinically significant,” said Dr. Walter M. Stadler, one of the study investigators based at the University of Chicago.

Interferon is the current standard for treating RCC, and “you get a very modest improvement in survival on the order of one month,” Stadler said.

“For years we were looking at things that didn’t work, “ he commented. “We now have drugs that work in this disease and I think that is incredibly exciting.”

RELATED STORIES:
Is milk thistle effective in cancer treatment?   Obesity drug ‘may fight cancer’   Aspirin reduces overall cancer and mortality rates   Snoring ‘can raise cancer risk five-fold’   New Synthetic Form of Protein Holds Promise to Stop Cancer Spread   Lung cancer tied to family risk of other cancers   Yttrium-90 to control hepatocarcinoma   Many Complex Linkages Between Smoking and Cancer   Childhood cancer survival linked to suicidality   Researchers Develop and Improve Techniques for Treating Cancer   Tackling a Hard-to-treat Childhood Cancer by Targeting Epigenetic Changes   Researchers Find Cancer News May Contribute To Confusion About Cancer   Some tumors contain factors that may block metastasis   Cancer Research Highlights   Study questions dioxin’s link to cancer   Clinical Trial Test Helps Measure Effectiveness of Treatment for Patients with Metastatic Cancer   New tool to speed cancer therapy approval available   Radionuclide treatment against small tumors and metastases   Fruit research yields way to curb cancer   New advances in the understanding of cancer progression   Moderate activity may reduce ovarian cancer risk   Bone marrow transplantation may increase cancer resistance in patients

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]